Chief Executive
James Barder is the Group’s Chief Executive. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations and leads commercial negotiations. He is also a Non-Executive Director of Caisson Investment Management and a Director of the Mary How Trust for Cancer Prevention.
Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James predominantly worked in the field of insurance and finance including firms he founded.
Over 25 years of experience in setting up, managing and running companies.
Executive Director and Head of R&D
Ken James is the Head of R&D. He oversees the development, regulatory and manufacturing strategies for the Group’s existing pipeline and the evaluation of early stage pipeline opportunities. He is also an Executive Director.
Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.
Over 40 years’ experience in the research, development and commercialisation of consumer healthcare products.
Finance Director, Chief Operating Officer and Company Secretary
Angela joined the Group in 2018. She leads the Group’s finance, HR and IT functions, inputs into commercial and financial strategy, leads the Group's compliance procedures and is a principal contact for shareholder and investor relations matters. She is also an Independent Non-Executive Director and Chair of the Audit Committee at AIM-listed Aptamer plc.
Senior financial roles in a diverse range of industries, including 7 years as UK Finance Director at Shield Therapeutics plc (quoted on AIM).
Over 15 years’ strategic and operational financial experience of developing and commercialising pharmaceutical products.
Non-Executive Chairman
John Clarke is the Chairman of Futura Medical plc. He chairs the Nominations Committee and is a member of the Audit Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc, Kind Consumer Holdings Limited and is a senior adviser to Helios Investment Partners LLP.
Retired from GSK as President of GSK Consumer Healthcare. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-Executive Chairman of Quantum Pharma plc, which was subsequently acquired by Clinigen plc.
Extensive experience of the healthcare sector, having worked at a senior level at GSK for more than 35 years.
Non-Executive Director
Jeff Needham is an Independent Non-Executive Director and Chair of the Remuneration Committee. He is also a member of the Nominations Committee. Jeff is currently on the Board of McKee Foods Corp.
President of Perrigo Consumer Self-Care Americas (including US) and Senior Vice President at Perrigo Company Plc, the US-based manufacturer and marketer of consumer healthcare products, and a board director of the Consumer Healthcare Products Association for 11years.
Over 35 years of experience in manufacturing and marketing of consumer healthcare products with strategic and corporate management expertise, with particular expertise in the US market.
Non-Executive Director
Andrew Unitt is an Independent Non-Executive Director and Chair of the Audit Committee. He is also a member of the Remuneration Committee and the Nominations Committee. Andrew is currently Independent Non-Executive director of AIM-listed company Oncimmune Holdings Plc.
Chief Financial Officer at the University of Nottingham until 2016. Andrew spent eleven years at Boots plc, where he was Managing Director and Finance Director for four years of Boots Healthcare International, its over the counter medicines business.
Over 20 years of experience as a Finance Director in a wide range of industries with strong financial experience and OTC market expertise.